Bioorganic & Medicinal Chemistry Letters
Synthesis and biological evaluation of 4b-(thiazol-2-yl)amino-40-O-
demethyl-4-deoxypodophyllotoxins as topoisomerase-II inhibitors
b,c,
Chun-Yan Sang a, Heng-Zhi Tian a, Yue Chen d, Jian-Fei Liu a, Shi-Wu Chen a, , Ling Hui
⇑
⇑
a School of Pharmacy, Lanzhou University, Lanzhou 730000, China
b Experimental Center of Medicine, General Hospital of Lanzhou Military Command, Lanzhou 730050, China
c Key Laboratory of Stem Cells and Gene Drug of Gansu Province, General Hospital of Lanzhou Military Command, Lanzhou 730050, China
d College of Life Science, Northwest Normal University, Lanzhou 730070, China
a r t i c l e i n f o
a b s t r a c t
A series of 4b-(thiazol-2-yl)amino-40-O-demethyl-4-deoxypodophyllotoxins were synthesized, and their
cytotoxicities were evaluated against four human cancer cell lines (A549, HepG2, HeLa, and LOVO cells)
and normal human diploid fibroblast line WI-38. Some of the compounds exhibited promising antitumor
activity and less toxicity than the anticancer drug etoposide. Among them, compounds 15 and 17 were
found to be the most potent synthetic derivatives as topo-II inhibitors, and induced DNA double-strand
breaks via the p73/ATM pathway as well as the H2AX phosphorylation in A549 cells. These compounds
also arrested A549 cells cycle in G2/M phase by regulating cyclinB1/cdc2(p34). Taken together, these
results show that a series of compounds are potential anticancer agents.
Article history:
Received 3 November 2017
Revised 5 December 2017
Accepted 6 December 2017
Available online xxxx
Keywords:
Podophyllotoxin
Topo-II inhibitors
DSBs
Ó 2017 Elsevier Ltd. All rights reserved.
Cell cycle arrest
Cancer has become one of the leading causes of death world-
wide, according to information from the World Health Organiza-
tion (WHO), it is estimated that there will be 12 million deaths
from cancer in 2030. Among them, it is estimated that more than
1 million people die of lung cancer annually and approximately
1.4 million individuals are diagnosed per year, 12% of whom are
new cases.1 Thus, there is an unmet need for novel therapies to
improve the prognosis of patients with lung cancer. Plant-derived
compounds are known to have curative potential.
DNA is the most vulnerable material in the cell, and DNA dam-
age induces a prominent route of cell death known as apoptosis.2
In clinical treatment, other than surgery, the mainstay of cancer
treatment to date has involved the use of DNA-damaging agents
in the form of radiation and systemic chemotherapy. Radiation is
responsible for approximately 40% of all cures achieved in cancer
patients.3 Commonly used DNA-damage-inducing chemotherapies
include platinum salts (carboplatin, cisplatin, and oxaliplatin) that
generate covalent cross-links between DNA bases,4 and topoiso-
merase-II (topo-II) inhibitors (etoposide and doxorubicin) that
generate topo–DNA adducts and DNA strand breaks.5 Topo-I inhi-
bitors induce DNA single-strand breaks, while topo-II inhibitors
induce DNA double-strand breaks (DSBs). H2AX, an evolutionarily
conserved variant of histone H2A, is a key histone that undergoes
various posttranslational modifications in response to DSBs.6 By
virtue of phosphorylation, H2AX marks the damaged DNA double
helix to facilitate local recruitment and retention of DNA repair
and chromatin remodeling factors and thus restore genomic
integrity.
Podophyllotoxin (PPT, 1), derived from the roots and rhizomes
of Podophyllum species, has cathartic, antirheumatic, and antiviral
properties, and pesticidal and antimitotic activity.7 Etoposide
(VP-16, 2) and teniposide (VM-26, 3, Fig. 1) are semisynthetic glu-
cosidic cyclic acetals of PPT currently used in chemotherapy for
various types of cancer, including small-cell lung cancer, testicular
carcinoma, lymphoma, and Kaposi’s sarcoma.8 Both of these com-
pounds block the catalytic activity of DNA topo-II by stabilizing a
cleavable enzyme–DNA-complex in which the DNA is cleaved
and covalently linked to enzyme.9 Although they are widely used
in the clinic, several problems hinder their clinical efficacy such
as drug resistance and poor water solubility. Therefore, there
remains a need for new PPT derivatives with anticancer activity
and improved water solubility. Extensive efforts have been made
researchers to address these limitations.10 Structure–activity rela-
tionship (SAR) experiments have unambiguously demonstrated
that C4 is the major molecular site tolerant to significant structural
diversification.11 Furthermore, the comparative molecular field
analysis (‘CoMFA’) models generated by Lee and coworkers
⇑
Corresponding authors at: School of Pharmacy, Lanzhou University, Lanzhou
730000, China (S.-W. Chen).
(L. Hui).
0960-894X/Ó 2017 Elsevier Ltd. All rights reserved.